|
|
 Previous Article | Table of Contents | Next Article 
Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal
human bone marrow
LK Ashman, AC Cambareri, LB To, RJ Levinsky and CA Juttner
Department of Microbiology and Immunology, University of Adelaide, South
Australia.
The c-kit proto-oncogene product is a member of the family of growth factor
receptors with intrinsic tyrosine kinase activity. In the mouse c-kit maps
to the W locus, which is known to be of central importance in
hematopoiesis. Monoclonal antibody (MoAb) YB5.B8, which was raised against
peripheral blood blast cells from a patient with acute myeloid leukemia
(AML), was recently shown to bind to the extracellular domain of the c-kit
product. This antibody does not bind detectably to normal peripheral blood
cells and identifies a sub-group of AML patients with poor prognosis. We
have used MoAb YB5.B8 to study the expression of c- kit by normal human
bone marrow cells by immunofluorescence and flow cytometry, and to isolate
multipotential and erythroid colony-forming cells. In a series of 11 normal
adult bone marrow specimens, MoAb YB5.B8 bound to 4.0% +/- 1.8% of the
cells in the low-density fraction. Dual-labeling experiments were performed
with YB5.B8, and CD33, CD34, and CD10 MoAbs. Three populations of cells
binding YB5.B8 could be identified based on their pattern of coexpression
of the other markers; ie, YB5.B8+/CD34+/CD33-, YB5.B8+/CD34+/CD33+ and
YB5.B8+/CD34+/CD33+. These populations had distinctive two-dimensional
light scatter characteristics and are likely to correspond to precursor
colony- forming cells, colony-forming cells, and maturing mast cells,
respectively. No cells binding both YB5.B8 and an MoAb to the early
lymphoid marker CD10 were found, implying that most early lymphoid cells do
not express c-kit. MoAbs to the c-kit protein should prove valuable in
multimarker studies of human hematopoietic stem and progenitor cells.
Definition of a reference range of c-kit expression in normal human bone
marrow will provide a sound basis for further studies of this marker in
diagnosis and prognosis in AML.
Volume 78,
Issue 1,
pp. 30-37,
07/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Stem Cells,
January 1, 2005;
23(1):
16 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hirschmann-Jax, A. E. Foster, G. G. Wulf, J. G. Nuchtern, T. W. Jax, U. Gobel, M. A. Goodell, and M. K. Brenner
A distinct "side population" of cells with high drug efflux capacity in human tumor cells
PNAS,
September 28, 2004;
101(39):
14228 - 14233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sotlar, L. Escribano, O. Landt, S. Mohrle, S. Herrero, A. Torrelo, U. Lass, H.-P. Horny, and B. Bultmann
One-Step Detection of c-kit Point Mutations Using Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping and Hybridization Probes
Am. J. Pathol.,
March 1, 2003;
162(3):
737 - 746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Coward, Y. Okayama, H. Sagara, S. J. Wilson, S. T. Holgate, and M. K. Church
NF-{kappa}B and TNF-{alpha}: A Positive Autocrine Loop in Human Lung Mast Cells?
J. Immunol.,
November 1, 2002;
169(9):
5287 - 5293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant
Mol. Cancer Ther.,
October 1, 2002;
1(12):
1115 - 1124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Scappini, F. Onida, H. M. Kantarjian, L. Dong, S. Verstovsek, M. J. Keating, and M. Beran
Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells
Clin. Cancer Res.,
December 1, 2001;
7(12):
3884 - 3893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Sotlar, T Marafioti, H Griesser, J Theil, C Aepinus, R Jaussi, H Stein, P Valent, and H-P Horny
Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia
Mol. Pathol.,
August 1, 2000;
53(4):
188 - 193.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H.-J. Buhring, P. J. Simmons, M. Pudney, R. Muller, D. Jarrossay, A. van Agthoven, M. Willheim, W. Brugger, P. Valent, and L. Kanz
The Monoclonal Antibody 97A6 Defines a Novel Surface Antigen Expressed on Human Basophils and Their Multipotent and Unipotent Progenitors
Blood,
October 1, 1999;
94(7):
2343 - 2356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sawai, K. Koike, H. H. Mwamtemi, T. Kinoshita, Y. Kurokawa, K. Sakashita, T. Higuchi, K. Takeuchi, M. Shiohara, T. Kamijo, et al.
Thrombopoietin Augments Stem Cell Factor-Dependent Growth of Human Mast Cells From Bone Marrow Multipotential Hematopoietic Progenitors
Blood,
June 1, 1999;
93(11):
3703 - 3712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yu, T. A. Fehniger, P. Fuchshuber, K. S. Thiel, E. Vivier, W. E. Carson, and M. A. Caligiuri
Flt3 Ligand Promotes the Generation of a Distinct CD34+ Human Natural Killer Cell Progenitor That Responds to Interleukin-15
Blood,
November 15, 1998;
92(10):
3647 - 3657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishizuka, H. Kawasome, N. Terada, K. Takeda, P. Gerwins, G. M. Keller, G. L. Johnson, and E. W. Gelfand
Stem Cell Factor Augments Fc{epsilon}RI-Mediated TNF-{alpha} Production and Stimulates MAP Kinases via a Different Pathway in MC/9 Mast Cells
J. Immunol.,
October 1, 1998;
161(7):
3624 - 3630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.C. Bene, M. Bernier, R.O. Casasnovas, G. Castoldi, W. Knapp, F. Lanza, W.D. Ludwig, E. Matutes, A. Orfao, C. Sperling, et al.
The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias
Blood,
July 15, 1998;
92(2):
596 - 599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Lyman and S. E. W. Jacobsen
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
Blood,
February 15, 1998;
91(4):
1101 - 1134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, et al.
Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors
Science,
January 23, 1998;
279(5350):
577 - 580.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Ferrao, T. J. Gonda, and L. K. Ashman
Expression of Constitutively Activated Human c-Kit in Myb Transformed Early Myeloid Cells Leads to Factor Independence, Histiocytic Differentiation, and Tumorigenicity
Blood,
December 1, 1997;
90(11):
4539 - 4552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Fehniger, W. E. Carson, E. Mrozek, and M. A. Caligiuri
Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells In Vivo
Blood,
November 1, 1997;
90(9):
3647 - 3653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Broudy
Stem Cell Factor and Hematopoiesis
Blood,
August 15, 1997;
90(4):
1345 - 1364.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. de Jong, Y. Westerman, G. Wagemaker, and A. W. Wognum
Coexpression of Kit and the Receptors for Erythropoietin, Interleukin 6 and GM-CSF on Hemopoietic Cells
Stem Cells,
July 1, 1997;
15(4):
275 - 285.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. Rappold, B. L. Ziegler, I. Kohler, S. Marchetto, O. Rosnet, D. Birnbaum, P. J. Simmons, A. C.W. Zannettino, B. Hill, S. Neu, et al.
Functional and Phenotypic Characterization of Cord Blood and Bone Marrow Subsets Expressing FLT3 (CD135) Receptor Tyrosine Kinase
Blood,
July 1, 1997;
90(1):
111 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
